We also simulated the effect of gosuranemab in a 52-week study in AD patients (Fig. S9), essentially leading to a slightly higher pharmacodynamic effect, i.e., a reduction of 0.4% in accumulated oligomeric tau uptake. The gene discussed is MAPT; the disease is Alzheimer disease.